NCT05666219

Reversal of Complete Heart Block With Aminophylline in Inferior Wall Myocardial Infarction Patients

Assessing the Impact of Aminophylline in the Reversal of Complete Heart Block Secondary to Inferior Wall MI in Atropine Resistant Patients: An Open Label Non-randomized Clinical Trial

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: National Institute of Cardiovascular Diseases, Pakistan · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this study, the investigator will evaluate the rate of reversal of complete heart block with aminophylline in atropine resistant patients with inferior wall myocardial infarction (MI)

Detailed description

Administration of Aminophylline can result in reversal of complete heart block in a significant number of atropine resistant patients with inferior wall MI. Hence, in this study our primary aim is to evaluate the rate of reversal of complete heart block with aminophylline in atropine resistant patients with inferior wall MI.

Conditions

• Complete Heart Block
• Inferior Wall Myocardial Infarction

Interventions

Type	Name	Description
DRUG	Aminophylline Injection	Injection Aminophylline IV 240 mg will be given over 10 minutes. After 1 hour, Aminophylline 240 mg second dose will be given over 10 minutes.

Timeline

• Start date: 2022-12-19
• Primary completion: 2023-12-18
• Completion: 2025-01-17
• First posted: 2022-12-27
• Last updated: 2025-05-25

Regulatory

• FDA-regulated drug study